Autolus Therapeutics (AUTL) Q1 2025 earnings summary

Executive summary

• Achieved $9 million in Q1 2025 product revenue from the U.S. launch of AUCATZYL, with 39 centers activated and over 90% coverage of U.S. medical lives; strong physician interest reported.

• Conditional marketing authorization for AUCATZYL granted in the U.K. in April 2025; EMA/EU regulatory decision expected in H2 2025, with European launch preparations underway.

• Early data in autoimmune diseases (lupus nephritis, SLE, MS) show promising efficacy and safety; Phase 2 lupus nephritis and Phase 1 progressive MS trials planned for late 2025.

• Cash, cash equivalents, and marketable securities totaled $516.6 million at quarter-end, supporting ongoing launches and clinical development.

• Net loss for Q1 2025 was $70.2 million, reflecting increased investment in commercialization and R&D.

Financial highlights

• Q1 2025 net product revenue was $9 million; cost of sales totaled $18 million, including deferred revenue and royalties.

• R&D expenses decreased to $26.7 million from $30.7 million year-over-year due to reclassification of manufacturing costs.

• SG&A expenses rose to $29.5 million from $18.2 million year-over-year, driven by commercialization efforts.

• Loss from operations was $65.2 million in Q1 2025, compared to $38.8 million in Q1 2024.

• Cash, cash equivalents, and marketable securities totaled $516.6 million as of March 31, 2025.

Outlook and guidance

• EMA decision for AUCATZYL in EU expected in H2 2025; UK commercial launch planned for H2 2025.

• Plans to initiate Phase 2 lupus nephritis and Phase 1 progressive MS trials by year-end 2025; pediatric ALL and full Phase 1 lupus nephritis data expected in H2 2025.

• Confident in cash position to fund launches and pivotal trials; additional capital may be needed for long-term profitability.